Korea Arlico Pharm Co.,Ltd. (KOSDAQ: 260660)

Korea Arlico Pharm Co.,Ltd. Statistics

Total Valuation

Korea Arlico Pharm Co.,Ltd. has a market cap or net worth of KRW 53.11 billion. The enterprise value is 83.90 billion.

Market Cap	53.11B
Enterprise Value	83.90B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Korea Arlico Pharm Co.,Ltd. has 15.33 million shares outstanding. The number of shares has decreased by -11.75% in one year.

Current Share Class	n/a
Shares Outstanding	15.33M
Shares Change (YoY)	-11.75%
Shares Change (QoQ)	+8.07%
Owned by Insiders (%)	39.79%
Owned by Institutions (%)	0.09%
Float	9.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.28
PB Ratio	0.62
P/TBV Ratio	0.69
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-11.16
EV / Sales	0.46
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.70

Financial Position

The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.55.

Current Ratio	1.17
Quick Ratio	0.61
Debt / Equity	0.55
Debt / EBITDA	n/a
Debt / FCF	-3.11
Interest Coverage	-5.89

Financial Efficiency

Return on equity (ROE) is -8.48% and return on invested capital (ROIC) is -4.49%.

Return on Equity (ROE)	-8.48%
Return on Assets (ROA)	-3.58%
Return on Capital (ROIC)	-4.49%
Revenue Per Employee	1.63B
Profits Per Employee	-67.15M
Employee Count	112
Asset Turnover	1.12
Inventory Turnover	2.82

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.07% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-38.07%
50-Day Moving Average	3,623.10
200-Day Moving Average	4,545.78
Relative Strength Index (RSI)	47.06
Average Volume (20 Days)	251,154

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Korea Arlico Pharm Co.,Ltd. had revenue of KRW 182.56 billion and -7.52 billion in losses. Loss per share was -501.22.

Revenue	182.56B
Gross Profit	97.25B
Operating Income	-9.35B
Pretax Income	-8.48B
Net Income	-7.52B
EBITDA	-2.83B
EBIT	-9.35B
Loss Per Share	-501.22

Balance Sheet

The company has 15.04 billion in cash and 45.83 billion in debt, giving a net cash position of -30.79 billion or -2,008.93 per share.

Cash & Cash Equivalents	15.04B
Total Debt	45.83B
Net Cash	-30.79B
Net Cash Per Share	-2,008.93
Equity (Book Value)	83.66B
Book Value Per Share	5,572.07
Working Capital	10.82B

Cash Flow

In the last 12 months, operating cash flow was -8.31 billion and capital expenditures -6.42 billion, giving a free cash flow of -14.73 billion.

Operating Cash Flow	-8.31B
Capital Expenditures	-6.42B
Free Cash Flow	-14.73B
FCF Per Share	-960.97

Margins

Gross margin is 53.27%, with operating and profit margins of -5.12% and -4.12%.

Gross Margin	53.27%
Operating Margin	-5.12%
Pretax Margin	-4.65%
Profit Margin	-4.12%
EBITDA Margin	-1.55%
EBIT Margin	-5.12%
FCF Margin	n/a

Dividends & Yields

Korea Arlico Pharm Co.,Ltd. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	11.75%
Shareholder Yield	11.75%
Earnings Yield	-14.47%
FCF Yield	-27.73%

Stock Splits

The last stock split was on June 15, 2021. It was a forward split with a ratio of 1.5.

Last Split Date	Jun 15, 2021
Split Type	Forward
Split Ratio	1.5

Scores

Korea Arlico Pharm Co.,Ltd. has an Altman Z-Score of 1.93. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.93
Piotroski F-Score	n/a